Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CRISPR Therapeutics AG CRSP

Healthcare Biotechnology
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this... see more

Recent & Breaking News (NDAQ:CRSP)

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 2, 2021

CRISPR Therapeutics Announces Transition of Chief Financial Officer

GlobeNewswire October 14, 2021

CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110(TM) in Relapsed or Refractory CD19+ B-cell malignancies

GlobeNewswire October 12, 2021

CRISPR Therapeutics to Host Virtual Event Highlighting CTX110(TM) Clinical Data

GlobeNewswire October 5, 2021

CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

GlobeNewswire October 1, 2021

CRISPR Therapeutics to Participate in the Chardan's 5th Annual Genetic Medicines Conference

GlobeNewswire September 28, 2021

CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference

GlobeNewswire August 5, 2021

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

GlobeNewswire July 29, 2021

CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich's Ataxia  

GlobeNewswire June 15, 2021

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001(TM) at European Hematology Association Annual Meeting

Business Wire June 11, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire May 25, 2021

Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001(TM) For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress

GlobeNewswire May 12, 2021

CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer

GlobeNewswire May 6, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire April 29, 2021

CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

GlobeNewswire April 28, 2021

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

GlobeNewswire April 27, 2021

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001(TM) for Transfusion-Dependent Beta Thalassemia

GlobeNewswire April 26, 2021

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001(TM) in Sickle Cell Disease and Beta Thalassemia

GlobeNewswire April 20, 2021

CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function

GlobeNewswire April 10, 2021

CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 6, 2021